Our Vision
Over 300 millions people worldwide suffer from the hepatitis B virus (HBV). There are approximately 860,000 – 905,000 new liver cancer diagnoses and ~700,000+ deaths worldwide per year. Nucorion Pharmaceuticals (“Nucorion”) is a privately held, clinical-stage biopharmaceutical company dedicated to discovering and developing targeted therapies for hepatitis B virus (HBV) infection and liver cancer through an innovative combination of the best-in-class small-molecule inhibitors and the first-in-class antibody immunotherapeutics.
Nucorion’s vision is to develop innovative medicines by leveraging the latest technologies, including AI, and deliver cures to patients of hepatitis, hepatocellular cancer, and other cancers.
Innovative Solutions for Health
Transforming lives through
cutting-edge therapies.
Support Resources
Care Guidance
We provide educational materials to empower patients about their health conditions.
Community Engagement
Our care guidance helps patients navigate their treatment options with confidence.
Financial Assistance
Join our community to connect with others facing similar health challenges.
Feedback Channels
We offer financial assistance programs to aid patients in need.
Detailed Overview of Our Therapies
Hepatitis
In combating hepatitis, we develop solutions to eliminate viral infections effectively and improve liver health.
Hepatocellular Carcinoma
Novel therapeutics targeting liver cancer cause by Hepatitis B, Hepatitis C, and cirrhosis.
Immunology
Our bispecific antibody and peptide solutions aim to bolster immune defense and response with precision.